INS and metabolic dysfunction-associated steatohepatitis: The ability of pioglitazone in improving insulin sensitivity has resulted in decreased blood glucose, serum fatty acids, and the resolution of non-alcoholic steatohepatitis in patients with type 2 diabetes or prediabetes [14-16], as well as nondiabetic patients [17].